Rodman & Renshaw reiterated its Dendreon DNDN Market Outperform rating and $63 price target in a research report published today.
In the report, Rodman & Renshaw states, "Although near-term volatility is inevitable, we believe that long-term,
the demand for Provenge will outstrip supply. In our opinion, shares of Dendreon should continue to climb higher as
quarterly sales updates meet or beat expectations and speculation surrounding a potential take out of the company
continues."
Shares of Dendreon were trading at $39.62 at the time of posting, down 2.18% from Wednesday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in